Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer
Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer
复制标题
低水平的 5-羟甲基胞嘧啶预示非小细胞肺癌预后不良
DOI：
10.3892/ol.2016.4474
复制
发表时间：
2016-06-01
期刊：
影响因子：
2.9
通讯作者：
Ding, Jianyong
中科院分区：
文献类型：
--
作者：
Liao, Yunfei;Gu, Jie;Ding, Jianyong
5-羟甲基胞嘧啶（5-hmC）的丢失先前已被证明与各种肿瘤的发生和进展有关。然而，其在非小细胞肺癌（NSCLC）中的作用仍不清楚。本研究采用免疫组化和斑点杂交技术检测5-hmC在NSCLC及癌旁正常肺组织中的表达水平，分析5-hmC与NSCLC临床病理特征的关系及5-hmC在NSCLC患者预后中的意义。采用斑点杂交法检测NSCLC组织中5-hmC的表达，结果显示NSCLC组织中5-hmC的表达水平较癌旁正常组织明显降低，组织芯片免疫组化结果进一步证实了这一点。进一步分析显示，65.38%（136/208）的胃癌组织中存在5-hmC低表达，且5-hmC低表达与淋巴结转移显著相关（P
The loss of 5-hydroxymethylcytosine (5-hmC) has previously been demonstrated to be implicated in the initiation and progression of various tumors. However, its role in non-small cell lung cancer (NSCLC) remains unknown. The present study aimed to determine the level of 5-hmC in NSCLC and their adjacent normal lung tissues by immunohistochemistry and dot-blot analysis; then the relationship between 5-hmC level and the clinicopathological features of NSCLC and the prognostic significance of 5-hmC level in NSCLC patients were analyzed. By employing the dot-blot analysis, a significant reduction of 5-hmC level in NSCLC tissues compared with the adjacent normal tissues was detected, which were further verified by the immunohistochemistry results on tissue microarrays. Further analyses demonstrated that 65.38% (136/208) presented with low 5-hmC level, and low 5-hmC level was significantly associated with lymph node metastasis (P